In the context of an ever-louder international debate on whether patients with severe forms of epilepsy should be allowed to use medical cannabis to manage their condition, the Food and Drug Administration have just officially approved one such drug. The Food and Drug Administration have just approved a cannabis-based drug for the first time.
Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a “high” and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome. In the new study comparing 2 doses of CBD to a placebo, the researchers reported a 41.9 percent reduction in “drop seizures”—a type of seizure that results in severe loss of muscle control and balance—in patients taking a 20 mg/kg/d CBD regimen, a 37.2 percent reduction in those on a 10 mg/kg/d CBD regimen, and a 17.2 percent reduction in a group given a placebo.
While a Food and Drug Administration advisory panel recently recommended pharmaceutical-grade cannabidiol (CBD) as a treatment for two rare forms of epilepsy, CBD medication is not the same thing as medical marijuana, which is more available than ever before and promoted for wide variety of health conditions. The American Epilepsy Society (AES) wants to alert the 3 million people with epilepsy about the myths and facts related to CBD medication – derived from one of the many compounds found in in cannabis (the marijuana plant) – and medical marijuana. Medical marijuana, which is now legal in 29 states as well as the District of Columbia, refers to the physician-prescribed use of the whole, unprocessed marijuana plant or its basic extracts to treat the symptoms of an illness and othe...
Cannabidiol is an effective and generally well-tolerated add-on treatment for drop seizures in patients with Lennox-Gastaut syndrome, according to research published in The Lancet. “Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications,” Elizabeth A. Thiele, MD, from the pediatric epilepsy program at Massachusetts General Hospital, and colleagues wrote. “No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome.”
Marijuana’s effect on the body has garnered more and more interest as it becomes legal for medical and recreational use in different states. People who are against marijuana legalization cite the potential for addiction and other dangerous side effects, but a new report may debunk this popularly-held belief. On Dec. 13, the World Health Organization (WHO) announced that a cannabis compound called cannabidiol (CBD) “could have therapeutic value” for epilepsy-related seizures. Additionally, the WHO says that CBD is not likely to be misused or create dependence, unlike other cannabis compounds like Tetra Hydro Cannabinol (THC).
Since medicinal cannabis has become a more commonplace alternative for a well-established list of ailments, patients are finding a place for it next to their Advil and Tums. But unlike many other chronic illnesses that can be managed with over-the-counter supplements, epilepsy requires a specific cocktail of chemicals not readily available at the local corner store.
Could endocannabinoids be the key to reducing seizures? Boosting our own natural marijuana – known as endocannabinoids – is safer than using cannabis to block epileptic seizures, a group of University of Malta researchers have found.
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder. Cannabidiol is a non-intoxicating substance among the several active compounds derived from Cannabis plants. This molecule can also be produced synthetically. The results of its use to treat Dravet syndrome are reported in the latest edition of the Proceedings of the National Academy of Sciences, PNAS.
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...
We are often judged by the company we keep, even unfairly. For decades, that has been the fate of cannabidiol, a chemical compound that has the bad luck to occur naturally in marijuana, the world’s most controversial plant. Because cannabidiol is subject to the same tight legal restrictions on personal and scientific use as is marijuana, its potential medical benefits have been underappreciated — at least up until now.
A medical cannabis product called RSHO-X dramatically reduced epileptic seizures in a Mexican study of Lennox-Gastaut syndrome, a severe form of childhood epilepsy that responds poorly to treatment. The study covered 39 patients who had daily seizures despite being treated with at least three anti-epileptic drugs. Seventeen percent of the participants had no seizures for at least four months, researchers said. Eighty-four percent had a 50 percent reduction in seizure activity. And more than half, 53 percent, saw their seizure activity drop by 75 percent.
After 2 years of delays, appeals and uncertainty about availability, high-CBD, low-THC Medical Cannabis grown in Florida will finally be available next week to patients with prescriptions. Trulieve, located in Tallahassee, Florida, have announced that they have received the first formal authorization from the Florida DOH (Department of Health) to commence sales and dispensary of medicinal cannabis products. These CBD products are approved for persons with uncontrollable seizures and cancer and possibly other conditions. Children with Dravet syndrome and intractable and other hard-to-treat types of Epilepsy are expected to be greatly helped by the availability of high-CBD cannabis derived medicine. For more information check out Orlando Weekly, Miami Herald, or Orlando Sentinel and many oth...